# Bemarituzumab

Source: https://onco.cc/drugs/bemarituzumab/  
OnCo record `bemarituzumab` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Bemarituzumab is an antibody against FGFR2b, a growth receptor overproduced in about a third of stomach cancers. It improved survival early in its phase 3 trial, but the gain faded with longer follow-up.

## Summary

Afucosylated IgG1 blocking FGFR2b ligand binding and enhancing ADCC. FORTITUDE-101: interim OS 17.9 vs 12.5 months (HR 0.61) in FGFR2b ≥10% 2+/3+ tumours, attenuated at updated analysis (ESMO 2025). Corneal adverse events are frequent. FORTITUDE-102 adds nivolumab. The regulatory path was still uncertain in September 2026.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-07
- Code: FPA144
- Modality: Monoclonal antibody (anti-FGFR2b)
- Mechanism: Blocks FGF ligand binding to FGFR2b and recruits NK-mediated ADCC.

## Sources

- Amgen topline announcement: https://www.amgen.com/newsroom/press-releases/2025/06/amgen-announces-positive-topline-phase-3-results-for-bemarituzumab-in-fibroblast-growth-factor-receptor-2b-fgfr2b-positive-firstline-gastric-cancer

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/)
- technologies: [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/)
- targets: [FGFR2](https://onco.cc/targets/fgfr2/)
- companies: [Amgen](https://onco.cc/companies/amgen/)
- pathways: [FGF / FGFR signalling](https://onco.cc/pathways/fgfr-signalling/), [Gastric cancer (KEGG map)](https://onco.cc/pathways/gastric-cancer-signalling/), [RAS / RAF / MEK / ERK (MAPK)](https://onco.cc/pathways/ras-mapk/)
- trials: [FORTITUDE-101](https://onco.cc/trials/fortitude-101/)

---
JSON: https://onco.cc/api/v1/entities/bemarituzumab.json